ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)

HKD 6.98

(-1.69%)

Net Debt Summary of ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s latest annual net debt in 2023 was -232.21 Million CNY , up 62.58% from previous year.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s latest quarterly net debt in 2024 Q2 was -160.85 Million CNY , up 7.28% from previous quarter.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported annual net debt of -620.59 Million CNY in 2022, up 4.49% from previous year.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported annual net debt of -649.78 Million CNY in 2021, down 0.0% from previous year.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported quarterly net debt of -160.85 Million CNY for 2024 Q2, up 7.28% from previous quarter.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported quarterly net debt of -232.21 Million CNY for 2023 Q4, up 1.86% from previous quarter.

Annual Net Debt Chart of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (2023 - 2021)

Historical Annual Net Debt of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (2023 - 2021)

Year Net Debt Net Debt Growth
2023 -232.21 Million CNY 62.58%
2022 -620.59 Million CNY 4.49%
2021 -649.78 Million CNY 0.0%

Peer Net Debt Comparison of ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Name Net Debt Net Debt Difference
Uni-Bio Science Group Limited -76.36 Million HKD -204.063%
CK Life Sciences Int'l., (Holdings) Inc. 5.26 Billion HKD 104.409%